The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

Trial Details

NCT ID
NCT04329728
Phase
PHASE1 / PHASE2
Sponsor
AVM Biotechnology Inc
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • AVM0703
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Whittier, California, United States|33.97918,-118.03284
  • Weeki Wachee, Florida, United States|28.51555,-82.57288

Key Eligibility Criteria

  • 1\. Age ≥12 years and weight ≥40 kg;
  • 2\. Histologically confirmed diagnosis per 2016 World Health Organization (WHO) classification of lymphoid neoplasms160 and per the 2016 WHO classi…
  • DLBCL, including arising from follicular lymphoma;
  • High-grade B-cell lymphoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →